Vertex Reaches Reimbursement Deal with UK for Casgevy Gene Therapy in Thalassemia

Patients in the U.K. with transfusion-dependent beta-thalassemia will have access to Vertex Pharmaceuticals’ gene editing therapy Casgevy, thanks to an agreement with the National Health Service on the price.